Merck, Inc.
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
- Conditions
- Interventions
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 45
- Registration Number
- NCT05030506
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital ( Site 0003), Tianjin, Tianjin, China
🇨🇳Beijing Cancer hospital-Digestive Oncology ( Site 0001), Beijing, Beijing, China
🇨🇳Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( S, Nanjing, Jiangsu, China
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
- Conditions
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 506
- Registration Number
- NCT05027074
- Locations
- 🇺🇸
Academic Medical Research Institute ( Site 0533), Los Angeles, California, United States
🇺🇸Fresenius Kidney Care Newhope Fountain Valley ( Site 0617), Fountain Valley, California, United States
🇺🇸DaVita Crescent Heights Dialysis Center ( Site 0574), Los Angeles, California, United States
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18)
- Conditions
- Interventions
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 72
- Registration Number
- NCT05017012
- Locations
- 🇨🇱
James Lind Centro de Investigación del Cáncer ( Site 0102), Temuco, Araucania, Chile
🇨🇱FALP-UIDO ( Site 0101), Santiago, Region M. De Santiago, Chile
🇿🇦Cancercare Rondebosch Oncology-Clinical trials ( Site 0055), Rondebosch, Western Cape, South Africa
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 146
- Registration Number
- NCT05008224
- Locations
- 🇺🇸
Stanford Cancer Center ( Site 0023), Palo Alto, California, United States
🇺🇸Northwestern Memorial Hospital ( Site 0002), Chicago, Illinois, United States
🇺🇸Texas Oncology-Plano East ( Site 0020), Plano, Texas, United States
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
- Conditions
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 604
- Registration Number
- NCT05007106
- Locations
- 🇺🇸
Memorial Sloan Kettering - Bergen ( Site 1025), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering - Monmouth ( Site 1022), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering - Basking Ridge ( Site 1023), Basking Ridge, New Jersey, United States
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 191
- Registration Number
- NCT05005442
- Locations
- 🇧🇷
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0601), Natal, Rio Grande Do Norte, Brazil
🇺🇸University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0021, Aurora, Colorado, United States
🇩🇰Aarhus Universitetshospital, Skejby-Blodsygdomme ( Site 0362), Aarhus, Midtjylland, Denmark
Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482-020)
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 17
- Registration Number
- NCT04995484
- Locations
- 🇺🇸
The Texas Liver Institute ( Site 0002), San Antonio, Texas, United States
🇺🇸Orlando Clinical Research Center ( Site 0001), Orlando, Florida, United States
A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT04994522
- Locations
- 🇺🇸
Orlando Clinical Research Center ( Site 0001), Orlando, Florida, United States
A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)
- Conditions
- Interventions
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT04980872
- Locations
- 🇺🇸
Texas Children's Hospital ( Site 0104), Houston, Texas, United States
🇺🇸Seattle Children's Hospital ( Site 0103), Seattle, Washington, United States
🇮🇹Ospedale Pediatrico Bambino Gesù-Centro Trials ( Site 0087), Rome, Roma, Italy
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 730
- Registration Number
- NCT04976634
- Locations
- 🇺🇸
University of Arizona Cancer Center-University of Arizona Cancer Center - North Campus ( Site 5047), Tucson, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center ( Site 5002), Duarte, California, United States
🇺🇸Cedars-Sinai Medical Center ( Site 5045), Los Angeles, California, United States